Silencing of int6 gene restores function of the ischaemic hindlimb in a rat model of peripheral arterial disease

Cardiovascular Research

Volumn 92, Issue 2, 2011, Pages 209-217

  Okamoto, Noriko ^a   Tanaka, Akane ^a   Jung, Kyungsook ^a   Karasawa, Kaoru ^a   Orito, Kensuke ^b   Matsuda, Akira ^a   Amagai, Yosuke ^a   Oida, Kumiko ^a   Ohmori, Keitaro ^a   Matsuda, Hiroshi ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b AZABU UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Gene silencing; Hypoxia; Ischaemia; Peripheral vascular disease

Indexed keywords

ALG 00412; ALG 00417; ALG 00418; ALG 00422; ALG 00425; CILOSTAZOL; FIBROBLAST GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INT6 SMALL INTERFERING RNA; SCATTER FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANGIOGRAPHY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GAIT; GAIT DISORDER; GENE; GENE SILENCING; HINDLIMB; INT6 GENE; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; MALE; NONHUMAN; PERIPHERAL CIRCULATION; PERIPHERAL ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; UPREGULATION;

ANGIOGENIC PROTEINS; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOOD FLOW VELOCITY; DISEASE MODELS, ANIMAL; EUKARYOTIC INITIATION FACTOR-3; GAIT; GENE SILENCING; GENE THERAPY; HINDLIMB; INJECTIONS, INTRAMUSCULAR; ISCHEMIA; LASER-DOPPLER FLOWMETRY; MALE; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; REGIONAL BLOOD FLOW; RNA, SMALL INTERFERING; TIME FACTORS;

EID: 80054116296     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr203     Document Type: Article

References (35)

1. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-3049. (Pubitemid 26411793)
2. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386.
3. Murabito JM, D'Agostino RB, Silbershatz H, Wilson PWF. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation 1997;96:44-49. (Pubitemid 27298402)
4. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 1990;82:1925-1931.
5. Shamoun F, Sural N, Abela G. Peripheral artery disease: therapeutic advances. Expert Rev Cardiovasc Ther 2008;6:539-553.
6. Tirziu D, Simons M. Angiogenesis in the human heart: gene and cell therapy. Angiogenesis 2005;8:241-251. (Pubitemid 41759149)
7. Emanueli C, Madeddu P. Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions. Br J Pharmacol 2001;133:951-958. (Pubitemid 32762403)
8. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001;8:181-189. (Pubitemid 32186129)
9. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-578. (Pubitemid 32250386)
10. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003;111:779-783. (Pubitemid 37074949)
11. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2a in development and disease. Cell Death Differ 2005;15:628-634.
12. Bonicalzi ME, Groulx I, de Paulsen N, Lee S. Role of exon 2-encoded b-domain of the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2001;276:1407-1416. (Pubitemid 32096572)
13. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC et al. Hypoxia inducible factor-a binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-25741.
14. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1a ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000;97:10430-10435.
15. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the b-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-427.
16. Chen L, Uchida K, Endler A, Shibasaki F. Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2a for degradation by hypoxia-and pVHL-independent regulation. J Biol Chem 2007;27:12707-12716. (Pubitemid 47100632)
17. Chen L, Endler A, Uchida K, Horiguchi S, Morizane Y, Iijima O et al. Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2a expression. Circulation 2010;122:910-919.
18. Orito K, Kishi M, Fujiki H, Nakazawa T, Imaizumi T, Kimura Y et al. A method for evaluating drug effects on intermittent claudication using a treadmill in rats with unilateral hindlimb artery occlusion. J Pharmacol Toxicol Methods 2004;49:25-29. (Pubitemid 37506052)
19. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82. (Pubitemid 27043825)
20. Aoki C, Hattori Y, Tomizawa A, Jojima T, Kasai K. Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo. J Atheroscler Thromb 2010;17: 503-509.
21. Orito K, Kurozumi S, Ishii I, Tanaka A, Sawada J, Matsuda H. A sensitive gait parameter for quantification of arthritis in rats. J Pharmacol Sci 2007;103:113-116. (Pubitemid 46175601)
22. Tanaka A, Jung K, Benyacoub J, Prioult G, Okamoto N, Ohmori K et al. Oral supplementation with Lactobacillus rhamnosus CGMCC 1.3724 prevents development of atopic dermatitis in NC/NgaTnd mice possibly by modulating local production of IFN-g. Exp Dermatol 2009;18:1022-1027.
23. Oliveira S, Høgset A, Storm G, Schiffelers RM. Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, in vitro and in vivo. Curr Pharm Des 2008;14:3686-3697.
24. Iwasaki K, Kojima K, Kodama S, Paz AC, Chambers M, Umezu M et al. Bioengineered three-layered robust and elastic artery using hemodynamically- equivalent pulsatile bioreactor. Circulation 2008;118 (14 Suppl):S52-S57.
25. Osawa M, Masuda M, Kusano K, Fujiwara K. Evidence for a role of platelet endothelial cell adhesion molecule-1 in endothelial cell mechanosignal transduction: is it a mechanoresponsive molecule? J Cell Biol 2002;158:773-785. (Pubitemid 34920115)
26. Fujiwara K. Platelet endothelial cell adhesion molecule-1 and mechanotransduction in vascular endothelial cells. J Intern Med 2006;259:373-380. (Pubitemid 43384228)
27. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992;20:900-906. (Pubitemid 23001455)
28. Reilly MP, Mohler ER III. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001;35:48-56. (Pubitemid 32216282)
29. Falconer TM, Eikelboom JW, Hankey GJ, Norman PE. Management of peripheral arterial disease in the elderly: focus on cilostazol. Clin Interv Aging 2008;3:17-23. (Pubitemid 351559800)
30. Kim MJ, Park KG, Lee KM, Kim HS, Kim SY, Kim CS et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 2005;45:552-556.
31. Hayashi K, Nakamura S, Morishita R, Moriguchi A, Aoki M, Matsumoto K et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000; 7:1664-1671.
32. Kawai K, Suzuki S, Tabata Y, Ikada Y, Nishimura Y. Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis. Biomaterials 2000;21:489-499. (Pubitemid 30067585)
33. Akeno N, Czyzyk-Krzeska MF, Gross TS, Clemens TL. Hypoxia induces vascular endothelial growth factor gene transcription in human osteoblast-like cells through the hypoxia-inducible factor-2a. Endocrinology 2001;142:959-962. (Pubitemid 32222447)
34. Wagner PD. Skeletal muscle angiogenesis. A possible role for hypoxia. Adv Exp Med Biol 2001;502:21-38. (Pubitemid 34234047)
35. Breen E, Tang K, Olfert M, Knapp A, Wagner P. Skeletal muscle capillarity during hypoxia: VEGF and its activation. High Alt Med Biol 2008;9:158-166. (Pubitemid 351913541)